Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Timbetasin - RegeneRx Biopharmaceuticals

Drug Profile

Timbetasin - RegeneRx Biopharmaceuticals

Alternative Names: Fx peptide; GBT-101; GBT-201; RGN-137; RGN-259; RGN-352; RGN-457; TB4; TB4 16-38; Thymosin B4; Thymosin beta 4-16-38; Thymosin beta-4; Thymosin-beta-4-RegeneRx-Biopharmaceuticals; Timbetasin-National-Institutes-of-Health-(USA)/RegeneRx-Biopharmaceuticals; Tß4 - RegeneRx Biopharmaceuticals; Tβ4

Latest Information Update: 28 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Institutes of Health (USA)
  • Developer Chonbuk National University; Defiante Farmaceutica; Lenus Therapeutics; RegeneRx Biopharmaceuticals; sigma-tau SpA; United States Army Medical Research Institute of Chemical Defense; Wayne State University; Zhejiang University
  • Class Anti-infectives; Anti-inflammatories; Anti-ischaemics; Antibronchitics; Antidementias; Antifibrotics; Eye disorder therapies; Foot disorder therapies; Heart failure therapies; Neuroprotectants; Peptide hormones; Proteins; Skin disorder therapies; Thymus hormones; Vascular disorder therapies
  • Mechanism of Action Actin modulators; Amyloid inhibitors; Angiogenesis inducing agents; Apoptosis inhibitors; Cell movement activators; Collagen stimulants; Heat-shock protein modulators; MicroRNA modulators; Nerve growth factor stimulants; NF-kappa B inhibitors; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Keratitis; Epidermolysis bullosa
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Dry eyes; Keratitis
  • Phase II Epidermolysis bullosa
  • Preclinical Alzheimer's disease; Corneal disorders
  • No development reported Acute kidney injury; Brain injuries; Burns; Chronic granulomatous disease; COVID 2019 infections; Diabetic neuropathies; Eye disorders; Multiple sclerosis; Musculoskeletal disorders; Myocardial infarction; Pressure ulcer; Pulmonary arterial hypertension; Septic shock; Stroke; Varicose ulcer
  • Discontinued Alopecia; Bronchiectasis; Cystic fibrosis; Diabetic foot ulcer; Diabetic retinopathy

Most Recent Events

  • 28 Dec 2023 No recent reports of development identified for preclinical development in Acute kidney injury in USA
  • 28 Dec 2023 No recent reports of development identified for preclinical development in Chronic-granulomatous-disease in USA (Intraperitoneal, Injection)
  • 28 Nov 2023 No recent reports of development identified for phase-I development in COVID-2019-infections in Unknown (Injection)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top